Developer docs
API playgroundTry for free, no card

Search company profiles

Attana

Full company profile

uuid0006okw

Namestring
Attana
Legal namestring
Attana
Websiteurl
attana.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

Attana is a Swedish biotechnology company headquartered in Stockholm that has developed proprietary third-generation biosensor technology for measuring how drug candidates bind to biological targets over time. Founded in 2002 and publicly listed on the NGM Growth Market under the ticker ATANA, the company operates with 11–50 employees and addresses the drug development value chain by providing binding kinetics testing that is positioned as a more realistic assessment than traditional endpoint binding assays. The platform is intended to help pharmaceutical and biotechnology developers select better drug candidates before committing capital to expensive clinical trial phases, with the explicit value proposition of reducing late-stage drug research failure rates.

The company's go-to-market is in active transition. Historically a research-oriented entity, Attana is repositioning to serve contract research organizations (CROs), pharmaceutical companies, and biotechnology firms through a subscription-based rental model that allows laboratories to access the binding kinetics technology without the upfront capital outlay of instrument purchase. Distribution is direct-to-laboratory, and a key patent approval was secured in Q1 2026 to underpin the commercial push. Primary customer segments are horizontal use cases — drug candidate selection, binding kinetics testing, and diagnostic analysis for drug development — rather than a single named anchor vertical.

Attana's financial profile reflects an early-stage commercial operation. Q1 2026 results disclosed declining sales and widened losses as the company invested in the CRO pivot, and in June 2026 the company raised approximately 24.2 million SEK via a preferential share emission (rights issue) secured largely through subscription commitments and a directed convertible to the main owner. The company currently serves customers primarily in Europe, and management has not publicly disclosed pricing or specific customer logos, leaving revenue concentration and absolute scale unverified.

Short descriptiontext

Attana is a Swedish biotech company that develops proprietary third-generation biosensor technology for measuring drug candidate binding kinetics, serving pharmaceutical developers and CROs seeking better candidate selection before clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
binding kinetics analysis, biosensor technology, drug candidate screening, preclinical testing services, biopharmaceutical analytics
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Biosensor Instruments
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Rental/Subscription Services
TypeSubscription Recurring
Description

Attana offers its binding kinetics testing technology to pharmaceutical and biotech laboratories through a rental model, generating recurring subscription revenues. This allows laboratories to access advanced testing without purchasing expensive instruments upfront.

di.se
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Attana develops and commercializes proprietary third-generation biosensor instruments that measure how drug candidates bind to biological targets over time. The company provides its binding kinetics testing technology to pharmaceutical, biotech, and contract research organization (CRO) laboratories, primarily through a subscription-based rental model that allows labs to use the technology without purchasing expensive instruments upfront.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces failure rate in drug research
+1 more record
Product overview1 text field

Attana is a Swedish biotech company that has developed proprietary binding kinetics testing technology. The company offers instruments that measure how drug candidates bind over time, providing a more realistic assessment than traditional testing methods. Attana is transitioning from a pure research entity toward offering its technology as a scalable, subscription-based rental service to pharmaceutical and biotech laboratories (CRO market). The company aims to help drug developers select better candidates before expensive clinical trial phases by providing advanced testing methods that reduce failure rates in drug research.

Product and service1 record
1Attana Biosensor Instruments
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bio-Rad supplies life-science research and clinical diagnostics instruments, including surface plasmon resonance and protein interaction tools used in pharma and academic labs alongside Attana's biosensor customers.

TypeEmerging player
Description

Repligen provides bioprocessing and analytics products, including SPR-based binding kinetics consumables, serving biopharma process development and analytical labs with adjacent offerings to Attana.

TypeBroad incumbent
Description

Waters manufactures analytical instruments (chromatography, mass spectrometry) widely used in pharma R&D and QC; while not a direct binding kinetics competitor, it shares the same instrument-purchasing customer base.

TypeEmerging player
Description

Evotec is a drug discovery CRO with end-to-end preclinical capabilities, including in vitro pharmacology and binding assays; comparable as both a potential CRO customer for Attana and a competing preclinical service provider.

TypeDirect peer
Description

Carterra provides high-throughput label-free SPR (LSA) instruments for antibody and binding kinetics characterization, directly competing with Attana's biosensor technology in preclinical drug discovery applications.

TypeBroad incumbent
Description

Lonza is a major CDMO/CRO serving pharma with discovery, manufacturing, and analytical services; representative of the large CRO/CMO customers Attana aims to reach with its subscription rental model.

TypeDirect peer
Description

Charles River is a large preclinical CRO offering discovery and pharmacology services; it represents the customer archetype Attana is targeting and also a potential commercialization partner or competitor in binding analytics.

TypeBroad incumbent
Description

Cytiva's Biacore label-free SPR platform is the dominant reference standard for binding kinetics and specificity analysis; directly comparable technology competing for the same CRO and pharma R&D accounts Attana targets.

TypeDirect peer
Description

Sartorius's Octet (FortéBio) systems are a leading label-free binding kinetics platform used in drug discovery and CRO workflows, directly overlapping Attana's biosensor offering for antibody and small-molecule characterization.

TypeBroad incumbent
Description

Bruker manufactures a broad portfolio of analytical and life-science instruments, including mass spectrometry and SPR platforms used for binding and molecular interaction studies in pharma and biotech labs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Attana

Biosensor Instrumentsattana.com

Attana is a Swedish biotech company that develops proprietary third-generation biosensor technology for measuring drug candidate binding kinetics, serving pharmaceutical developers and CROs seeking better candidate selection before clinical trials.

What Attana does

Attana is a Swedish biotechnology company headquartered in Stockholm that has developed proprietary third-generation biosensor technology for measuring how drug candidates bind to biological targets over time. Founded in 2002 and publicly listed on the NGM Growth Market under the ticker ATANA, the company operates with 11–50 employees and addresses the drug development value chain by providing binding kinetics testing that is positioned as a more realistic assessment than traditional endpoint binding assays. The platform is intended to help pharmaceutical and biotechnology developers select better drug candidates before committing capital to expensive clinical trial phases, with the explicit value proposition of reducing late-stage drug research failure rates.

The company's go-to-market is in active transition. Historically a research-oriented entity, Attana is repositioning to serve contract research organizations (CROs), pharmaceutical companies, and biotechnology firms through a subscription-based rental model that allows laboratories to access the binding kinetics technology without the upfront capital outlay of instrument purchase. Distribution is direct-to-laboratory, and a key patent approval was secured in Q1 2026 to underpin the commercial push. Primary customer segments are horizontal use cases — drug candidate selection, binding kinetics testing, and diagnostic analysis for drug development — rather than a single named anchor vertical.

Attana's financial profile reflects an early-stage commercial operation. Q1 2026 results disclosed declining sales and widened losses as the company invested in the CRO pivot, and in June 2026 the company raised approximately 24.2 million SEK via a preferential share emission (rights issue) secured largely through subscription commitments and a directed convertible to the main owner. The company currently serves customers primarily in Europe, and management has not publicly disclosed pricing or specific customer logos, leaving revenue concentration and absolute scale unverified.

Attana firmographics

Firmographics
Name
Attana
Legal name
Attana
Website
https://attana.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Attana is a Swedish biotech company that develops proprietary third-generation biosensor technology for measuring drug candidate binding kinetics, serving pharmaceutical developers and CROs seeking better candidate selection before clinical trials.
Ownership category
akta.pro rank

Attana industry classification

Industry
Product category
Biosensor Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Binding kinetics analysis
  • Biosensor technology
  • Drug candidate screening
  • Preclinical testing services
  • Biopharmaceutical analytics

Where Attana is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Markets served

Attana business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Technology Rental/Subscription Services: Attana offers its binding kinetics testing technology to pharmaceutical and biotech laboratories through a rental model, generating recurring subscription revenues. This allows laboratories to access advanced testing without purchasing expensive instruments upfront.

Go-to-market motion2 records

Distribution channels1 record

Attana product offering

Product offering

Core offering

Attana develops and commercializes proprietary third-generation biosensor instruments that measure how drug candidates bind to biological targets over time. The company provides its binding kinetics testing technology to pharmaceutical, biotech, and contract research organization (CRO) laboratories, primarily through a subscription-based rental model that allows labs to use the technology without purchasing expensive instruments upfront.

Product overview

Attana is a Swedish biotech company that has developed proprietary binding kinetics testing technology. The company offers instruments that measure how drug candidates bind over time, providing a more realistic assessment than traditional testing methods. Attana is transitioning from a pure research entity toward offering its technology as a scalable, subscription-based rental service to pharmaceutical and biotech laboratories (CRO market). The company aims to help drug developers select better candidates before expensive clinical trial phases by providing advanced testing methods that reduce failure rates in drug research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Attana Biosensor Instruments

Quantifiable outcome

  • Reduces failure rate in drug research
  • +1 more outcomes

Companies that use Attana

Customer profile

Segments3 records

Ideal customer profiles3 records

Attana technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Attana partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves9 records

Expansion highlights5 records

Attana competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad supplies life-science research and clinical diagnostics instruments, including surface plasmon resonance and protein interaction tools used in pharma and academic labs alongside Attana's biosensor customers.
  • Waters Corporation: Waters manufactures analytical instruments (chromatography, mass spectrometry) widely used in pharma R&D and QC; while not a direct binding kinetics competitor, it shares the same instrument-purchasing customer base.
  • Lonza: Lonza is a major CDMO/CRO serving pharma with discovery, manufacturing, and analytical services; representative of the large CRO/CMO customers Attana aims to reach with its subscription rental model.
  • Cytiva (formerly GE Healthcare Life Sciences): Cytiva's Biacore label-free SPR platform is the dominant reference standard for binding kinetics and specificity analysis; directly comparable technology competing for the same CRO and pharma R&D accounts Attana targets.
  • Bruker: Bruker manufactures a broad portfolio of analytical and life-science instruments, including mass spectrometry and SPR platforms used for binding and molecular interaction studies in pharma and biotech labs.

Emerging players

  • Repligen: Repligen provides bioprocessing and analytics products, including SPR-based binding kinetics consumables, serving biopharma process development and analytical labs with adjacent offerings to Attana.
  • Evotec: Evotec is a drug discovery CRO with end-to-end preclinical capabilities, including in vitro pharmacology and binding assays; comparable as both a potential CRO customer for Attana and a competing preclinical service provider.

Direct peers

  • Carterra: Carterra provides high-throughput label-free SPR (LSA) instruments for antibody and binding kinetics characterization, directly competing with Attana's biosensor technology in preclinical drug discovery applications.
  • Charles River Laboratories: Charles River is a large preclinical CRO offering discovery and pharmacology services; it represents the customer archetype Attana is targeting and also a potential commercialization partner or competitor in binding analytics.
  • Sartorius (including FortéBio / Octet): Sartorius's Octet (FortéBio) systems are a leading label-free binding kinetics platform used in drug discovery and CRO workflows, directly overlapping Attana's biosensor offering for antibody and small-molecule characterization.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights5 records

Customer concentration

Attana social profiles

Digital presence

Attana financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Attana leadership team

Management profile

Number of profiles

Profiles1 record

Attana funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Attana M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Attana

What does Attana do?

Attana develops and commercializes proprietary third-generation biosensor instruments that measure how drug candidates bind to biological targets over time. The company provides its binding kinetics testing technology to pharmaceutical, biotech, and contract research organization (CRO) laboratories, primarily through a subscription-based rental model that allows labs to use the technology without purchasing expensive instruments upfront.

Is Attana a public or private company?

Attana is a public company. It is classified as public and is currently operating.

When was Attana founded?

Attana was founded in 2002. It employs 11 to 50 people.

Where is Attana based?

Attana is headquartered in Stockholm, Sweden, in the Europe region.

How does Attana make money?

One revenue line is on record: technology Rental/Subscription Services.

Who are Attana's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Waters Corporation, Lonza, Cytiva (formerly GE Healthcare Life Sciences) and Bruker. Emerging players are Repligen and Evotec. Direct peers are Carterra, Charles River Laboratories and Sartorius (including FortéBio / Octet).

Does Attana have an API?

No public API is recorded for Attana.

What industry is Attana in?

Attana's product category is Biosensor Instruments. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.com#26-86 Consolidation of shares in Attana ABAttana AB's extraordinary general meeting on October 30, 2026 approved a 1:10,000 share consolidation. The record date is November 24, 2026, with trading on November 20, 2026, and the new ISIN code SE0031013099 takes effect November 23, 2026.Dealroom.coFinland's BioNavis takes 64% of Sweden's Attana in reverse acquisition | Dealroom NewsAttana agreed to acquire all shares in BioNavis in a reverse acquisition, with BioNavis owners holding about 64% of the combined company. BioNavis reported 2025 net sales of US$1.7M and operating profit of US$435.2K, while Attana's sales fell 40% to US$302.2K. Closing is expected around December 22.Dagens industriStrategerna: Håll koll på detta i rapporternaBioteknikbolaget Attana is conducting an emission to finance its transition and expansion into new markets, focusing on its diagnostic analysis technology for drug development. The company aims to reduce the failure rate in drug research by providing more advanced testing methods, and its strategy includes offering a scalable, subscription-based service to laboratories.Dagens industriKursraketen fortsätter rasa – utan nyheterBiotech company Attana, listed on NGM Growth Market, is conducting a rights issue of approximately 24.2 MSEK to finance its transition from an advanced research company to a commercial player targeting contract research organizations (CROs). The company's technology measures how drug candidates bind over time, helping pharmaceutical companies select better candidates earlier in the development process. The emission is secured to approximately 57.9 percent, with terms of 1 unit (10 new shares) for 10 rights at 0.03 SEK per unit.Dagens industriFörsvar tyngde EuropabörsernaEuropean stock markets showed mixed performance on Wednesday, with the Stoxx 600 index rising 0.1 percent while Frankfurt bucked the trend, weighed down by defense stocks. Biopharmaceutical and biotech company Attana announced a rights issue of approximately 24.2 million SEK to finance its strategic shift toward serving contract research organizations (CROs) in the drug development market. The company, listed on NGM Growth Market, aims to leverage its proprietary binding analysis technology to help pharmaceutical developers select drug candidates more effectively before expensive clinical trial phases.Dagens industriNytt säljråd för Epiroc – här är dagens rekarSwedish biotech company Attana, listed on NGM Growth Market, is conducting a new share issuance of approximately 24.2 MSEK to finance its strategic shift toward the commercial Contract Research Organization (CRO) market. The company is repositioning away from being a pure research entity toward offering its binding kinetics testing technology to drug development companies through a rental model that generates recurring revenues. UBS also issued a new sell recommendation for Swedish mining equipment company Epiroc, while Barclays upgraded its recommendation for telecom operator Telia, according to a brief summary of Tuesday's analyst recommendations.Dagens industriFem saker att ha koll på innan börsen öppnarBiotech company Attana, listed on NGM Growth Market, is conducting a rights issue of approximately 24.2 MSEK to finance its transition toward a more commercial focus on contract research laboratories (CROs) in the pharmaceutical and biotech sector. The company is leveraging its proprietary technology that measures how drug candidates bind over time, aiming to help labs select better candidates before expensive development phases. The subscription period runs from June 12 to June 26, 2026, with the issue secured to approximately 57.9 percent through subscription commitments and a directed convertible to the main owner.Dagens industriTunga inflationssiffran avrundar AlmedalsveckanSwedish biotech company Attana, listed on NGM Growth Market, is conducting a rights issue of approximately 24.2 million SEK to finance its strategic shift toward the commercial contract research organization (CRO) market, with the offering secured at about 57.9 percent through subscription commitments and a convertibel to the main owner. The biotechnology firm, which has developed instruments measuring drug candidate binding dynamics over time, aims to generate recurring revenues by offering its technology to pharmaceutical and biotech laboratories on a rental model. The subscription period runs from June 12 to June 26, 2026, with unit rights trading until June 23.Dagens industriStockholmsbörsen tappar fartSwedish biotech company Attana, listed on NGM Growth Market, is conducting a preferential share emission of approximately 24.2 million SEK to finance its strategic transition toward the commercial contract research organization (CRO) market. The company has developed technology that measures how drug candidates bind over time, offering a more realistic assessment than traditional tests, and is now shifting focus from pure research to sales-oriented commercial operations. The subscription-based model aims to generate recurring revenue and enable scalability by allowing laboratories to test the technology without purchasing expensive instruments upfront.news.cision.com#26-39 Unit issue in Attana ABAttana AB's board approved a unit issue with preferential rights for existing shareholders. Shareholders receive three unit rights per share, with a subscription price of 0.003 SEK per share. Trading in unit rights runs from June 12 to June 24, 2026, and paid subscribed units from June 12 to July 17, 2026.